Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently.
From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.
Also check out: Diamond Hill Capital Undervalued Stocks Diamond Hill Capital Top Growth Companies Diamond Hill Capital High Yield stocks, and Stocks that Diamond Hill Capital keeps buying
| Currently 0.00/512345 Rating: 0.0/5 (0 votes) |
Subscribe via Email 
Subscribe RSS Comments Please leave your comment: More GuruFocus Links
| Latest Guru Picks | Value Strategies |
| Warren Buffett Portfolio | Ben Graham Net-Net |
| Real Time Picks | Buffett-Munger Screener |
| Aggregated Portfolio | Undervalued Predictable |
| ETFs, Options | Low P/S Companies |
| Insider Trends | 10-Year Financials |
| 52-Week Lows | Interactive Charts |
| Model Portfolios | DCF Calculator |
RSS Feed  | Monthly Newsletters |
| The All-In-One Screener | Portfolio Tracking Tool |
| Latest Guru Picks | Value Strategies |
| Warren Buffett Portfolio | Ben Graham Net-Net |
| Real Time Picks | Buffett-Munger Screener |
| Aggregated Portfolio |
Subscribe to:
Post Comments (Atom)
|
No comments:
Post a Comment